Brief: Tenaya Therapeutics Q2 Loss Per Share $0.69
10/08/2022 21:57
Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
* TENAYA THERAPEUTICS - EXPECTS CURRENT CASH, INVESTMENTS IN
MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND CURRENT
OPERATING PLAN AT LEAST INTO H2 2023
* Q2 LOSS PER SHARE $0.69
* Q2 EARNINGS PER SHARE VIEW $-0.76 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX8QXqh6
Further company coverage: TNYA.O
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027